CL-278474

CAS No. 58125-33-0

CL-278474( —— )

Catalog No. M35308 CAS No. 58125-33-0

CL-278474 (compound I-79) is a potent inhibitor of β-N-acetylhexosaminidase OfHex1. CL-278474 can be used in control of insect.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 178 Get Quote
5MG 255 Get Quote
10MG 374 Get Quote
25MG 545 Get Quote
50MG 762 Get Quote
100MG 1017 Get Quote
500MG 2034 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CL-278474
  • Note
    Research use only, not for human use.
  • Brief Description
    CL-278474 (compound I-79) is a potent inhibitor of β-N-acetylhexosaminidase OfHex1. CL-278474 can be used in control of insect.
  • Description
    OfHex1-IN-2 (compound I-79) is a potent β-N-acetylhexosaminidase OfHex1 inhibitor. OfHex1-IN-2 can be used in control of insect.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    58125-33-0
  • Formula Weight
    303.42
  • Molecular Formula
    C16H21N3OS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(CN1CCCCC1)NC1=C(C#N)C2=C(CCCC2)S1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang Li, et al. The application of 4,5,6,7- tetrahydro benzo thiophenes. CN110313477A.
molnova catalog
related products
  • Glycocholic Acid Sod...

    Glycocholic Acid Sodium Salt is a conjugated bile salt and ionic biologic detergent. It is involved in the emulsification of fats.

  • 2-Hydroxymethyl-5-hy...

    2-Hydroxymethyl-5-hydroxypyridine is isolated from the the matured, ripened and dried seeds of S. lychnophora.

  • Disitamab vedotin

    Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.